Startseite Kongressberichte 2020 All-Virtual 62nd ASH Annual Meeting and Exposition Late-Breaking Abstracts Session

Late Breaking Abstract Session

Abstracts presented:

LBA-1 Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms

Nicholas Williams, Joe Lee, Luiza Moore, et al. and Jyoti Nangalia

 

LBA-2 A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate. the Flight Trial

Charlotte A Bradbury, Rosemary Greenwood, Julie Pell, et al.

 

LBA-3 Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia

Lindsey Montefiori, Sonja Seliger, Zhaohui Gu, et al.

 

LBA-4 Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs)

Andreas Hochhaus, Carla Boquimpani, Delphine Rea, et al.

 

LBA-5 ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Diletta Fontana, Mario Mauri, Rossella Renso, et al.

 

LBA-6 First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, Michael Recht, Nigel S. Key, et al.